FG
Felipe Galvez-Cancino
University of Oxford, University College London, Stanford University, Science & Life Foundation, University of Chile
Research areas: Immunology and Microbiology · Immunology · Cancer Immunotherapy and Biomarkers · Immunotherapy and Immune Responses · T-cell and B-cell Immunology
0000-0001-8417-1891
Employment
- 2024 - Present
-
UCL Postdoc2018 - 2024
-
Stanford University PhD student2016 - 2016
-
Fundación Ciencia and Vida PhD Student2014 - 2018
Education
- 2016 - 2016
-
Science & Life Foundation PhD in Biotechnology2014 - 2018
-
Universidad de Chile Pharmacist2007 - 2013
Projects & Funding
Projects & funding information is unavailable.
Publications (49)
- FasL-Mediated Death of Activated Intratumoral T Cells Drives Secondary Resistance to Cancer Immunotherapy Save
- Engineering and Improving Anti–CTLA-4 Checkpoint Inhibitors Save
- Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy Save
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models. Save
- Retraction Note: Antibodies against endogenous retroviruses promote lung cancer immunotherapy. Save
- Regulatory T Cell Depletion in Cancer: Challenges, Opportunities, and Future Directions for Antibody Development. Save
- Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic. Save
- The Dark Side of NK Cells in Cancer Immunotherapy Save
- Subclonal immune evasion in non-small cell lung cancer. Save
- Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies Save
- Regulatory T cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies. Save
- Clonal driver neoantigen loss under EGFR TKI and immune selection pressures. Save
- Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. Save
- MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution Save
- Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx. Save
- Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Save
- Long-term efficacy of adoptive cell therapy is determined by host CD8+T cells and undermined by lymphodepleting preconditioning Save
- Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models. Save
- The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma. Save
- Fcγ receptors and immunomodulatory antibodies in cancer. Save